The global central nervous system treatment market size was estimated to be USD 136.42 billion in 2023 and is expected to reach at USD 270.48 billion by 2034 with a CAGR of 6.42% during the forecast period 2024-2034. The increasing incidence of mental health issues, lifestyle-related CNS disorders like anxiety, depression, and hypertension, a growing aging population prone to chronic illnesses, a rise in Alzheimer's and Parkinson's diseases, the popularity of generic neurological drugs in developing nations due to their affordability, swift advancements in CNS treatment methods, increased development of gene therapy and neural transplantation techniques, the introduction of innovative drug delivery systems, heightened government and non-government efforts to raise awareness about central nervous system disorders, escalating investments in new drug development, an increased awareness among the public regarding neurodegenerative conditions, and surge in regulatory approval of novel drugs for central nervous system treatment are some of the key factors boosting the market growth.
Surge in regulatory approval of novel drugs for central nervous system treatment is predicted to boost the market growth during the forecast period. For instance, in August 2022, Health Canada has granted approval to Paladin Labs Inc for its New Drug Submission (NDS) application for carbamate. This medication is intended as an adjunctive therapy for adults with epilepsy experiencing partial-onset seizures that are not effectively controlled with conventional treatments.
By drug class, immunomodulators was the highest revenue-grossing segment in the global central nervous system treatment market in 2023 owing to continuous innovation and the development of therapeutic molecules for the treatment of various diseases are on the rise, accompanied by an increase in collaborations and research and development efforts. Additionally, antidepressants is predicted to grow at fastest CAGR during the forecast period owing to the rising occurrence of mental health issues, an increasing awareness regarding mental health, and a growing number of regulatory approvals. For instance, in February 2023, Sage Therapeutics, Inc. and Biogen Inc. have obtained acceptance from the United States FDA for their New Drug Application (NDA) for zuranolone, intended for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
By disease, neurodegenerative diseases was the highest revenue-grossing segment in the global central nervous system treatment market in 2023 owing to the prevalence of neurodegenerative diseases is on the rise, particularly with an increasing incidence of conditions such as Parkinson's disease, Alzheimer's disease, and multiple sclerosis. The expanding geriatric population, a robust pipeline of therapeutic developments, and the escalating number of regulatory approvals further contribute to this trend. For instance, in January 2023, The U.S. FDA has granted Accelerated Approval for the 100 mg/mL intravenous injection of lecanemab-irmb (LEQEMBI), a collaboration between Eisai Co., Ltd. and Biogen Inc. This humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody is designed to target aggregated soluble and insoluble forms of amyloid beta (Aβ) and is indicated for the treatment of Alzheimer's disease (AD). Additionally, mental health is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of anxiety disorders, epilepsy, and psychotic disorders, leading to an increased demand for innovative drugs. Additionally, there is a rising awareness surrounding mental health issues.
By drug type, non-biologics was the highest revenue-grossing segment in the global central nervous system treatment market in 2023 owing to the comparatively lower imposition of regulations by regulatory bodies for approval compared to biologics, coupled with a growing prevalence of neurological diseases. Strong government support and favorable health reimbursement further contribute to this trend. For instance, in January 2023, Biogen Inc. and Alcyone Therapeutics have entered into a collaboration and licensing agreement for Alcyone's ThecaFlex DRx System, a medical device implanted for the subcutaneous administration of antisense oligonucleotide (ASO) medicines into the intrathecal region. The partnership seeks to leverage the capabilities of the ThecaFlex DRx System to improve the treatment process and increase availability for a broader range of people affected by neurological disorders, including amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). Additionally, biologics is predicted to grow at fastest CAGR during the forecast period owing to the existence of promising pipeline candidates and government support play key roles in the development and approval of biologic central nervous system (CNS) drugs.
By distribution channel, hospital pharmacy was the highest revenue-grossing segment in the global central nervous system treatment market in 2023 owing to the increasing preference for treatment in hospital settings, higher sales revenue generated from the distribution channel of prescription drugs, and a growing trend of collaborations among market players are notable trends. For instance, in January 2022, Acadia Pharmaceuticals Inc. and Stoke Therapeutics Inc. have entered into a partnership to explore, develop, and bring to market novel RNA-based therapeutics for the potential treatment of severe and rare genetic neurodevelopmental central nervous system (CNS) diseases. The collaboration includes the study of SYNGAP1 syndrome, Rett syndrome (MECP2), and an undisclosed neurodevelopmental target of shared interest. Additionally, retail pharmacy is predicted to grow at fastest CAGR during the forecast period owing to a growing accessibility to prescription drugs, facilitated by the availability of discounts provided by large retail pharmacy chains.
North America region is anticipated for the highest revenue share during the forecast period owing to the prevalence of neurodegenerative disorders and other central nervous system (CNS) diseases is on the rise, particularly in the case of Parkinson's disease. The market is characterized by the presence of numerous leading players, an increase in the development of innovative therapies, a growing awareness among the public regarding mental health, the existence of a robust pipeline of potential products, and government & non-government organizations are actively mobilizing funds to support the development and authorization of central nervous system (CNS) therapeutics. For instance, in May 2022, Minoryx has secured a funding of USD 55.4 million (EUR 51 million) to facilitate the marketing authorization applications and readiness for the launch of their therapy for X-linked Adrenoleukodystrophy (X-ALD), focusing on orphan central nervous system (CNS) disorders. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increase in government investments aimed at enhancing healthcare infrastructure. Additionally, the growing population of patients with unmet medical needs benefits from free-of-cost treatments provided by various non-profit organizations, particularly for central nervous system diseases. The government is increasingly prioritizing efforts to raise awareness about mental health and CNS therapeutics and surge in collaborations within market players. For instance, in September 2023, Sun Pharma has disclosed that one of its wholly-owned subsidiaries has engaged in a licensing agreement with US-based Pharmazz Inc. This collaboration aims to introduce the Sovateltide drug, used for the treatment of acute cerebral ischemic stroke, in the Indian market.
Surge in regulatory approval of novel drugs for central nervous system treatment is predicted to boost the market growth during the forecast period. For instance, in August 2022, Health Canada has granted approval to Paladin Labs Inc for its New Drug Submission (NDS) application for carbamate. This medication is intended as an adjunctive therapy for adults with epilepsy experiencing partial-onset seizures that are not effectively controlled with conventional treatments.
By drug class, immunomodulators was the highest revenue-grossing segment in the global central nervous system treatment market in 2023 owing to continuous innovation and the development of therapeutic molecules for the treatment of various diseases are on the rise, accompanied by an increase in collaborations and research and development efforts. Additionally, antidepressants is predicted to grow at fastest CAGR during the forecast period owing to the rising occurrence of mental health issues, an increasing awareness regarding mental health, and a growing number of regulatory approvals. For instance, in February 2023, Sage Therapeutics, Inc. and Biogen Inc. have obtained acceptance from the United States FDA for their New Drug Application (NDA) for zuranolone, intended for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
By disease, neurodegenerative diseases was the highest revenue-grossing segment in the global central nervous system treatment market in 2023 owing to the prevalence of neurodegenerative diseases is on the rise, particularly with an increasing incidence of conditions such as Parkinson's disease, Alzheimer's disease, and multiple sclerosis. The expanding geriatric population, a robust pipeline of therapeutic developments, and the escalating number of regulatory approvals further contribute to this trend. For instance, in January 2023, The U.S. FDA has granted Accelerated Approval for the 100 mg/mL intravenous injection of lecanemab-irmb (LEQEMBI), a collaboration between Eisai Co., Ltd. and Biogen Inc. This humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody is designed to target aggregated soluble and insoluble forms of amyloid beta (Aβ) and is indicated for the treatment of Alzheimer's disease (AD). Additionally, mental health is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of anxiety disorders, epilepsy, and psychotic disorders, leading to an increased demand for innovative drugs. Additionally, there is a rising awareness surrounding mental health issues.
By drug type, non-biologics was the highest revenue-grossing segment in the global central nervous system treatment market in 2023 owing to the comparatively lower imposition of regulations by regulatory bodies for approval compared to biologics, coupled with a growing prevalence of neurological diseases. Strong government support and favorable health reimbursement further contribute to this trend. For instance, in January 2023, Biogen Inc. and Alcyone Therapeutics have entered into a collaboration and licensing agreement for Alcyone's ThecaFlex DRx System, a medical device implanted for the subcutaneous administration of antisense oligonucleotide (ASO) medicines into the intrathecal region. The partnership seeks to leverage the capabilities of the ThecaFlex DRx System to improve the treatment process and increase availability for a broader range of people affected by neurological disorders, including amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA). Additionally, biologics is predicted to grow at fastest CAGR during the forecast period owing to the existence of promising pipeline candidates and government support play key roles in the development and approval of biologic central nervous system (CNS) drugs.
By distribution channel, hospital pharmacy was the highest revenue-grossing segment in the global central nervous system treatment market in 2023 owing to the increasing preference for treatment in hospital settings, higher sales revenue generated from the distribution channel of prescription drugs, and a growing trend of collaborations among market players are notable trends. For instance, in January 2022, Acadia Pharmaceuticals Inc. and Stoke Therapeutics Inc. have entered into a partnership to explore, develop, and bring to market novel RNA-based therapeutics for the potential treatment of severe and rare genetic neurodevelopmental central nervous system (CNS) diseases. The collaboration includes the study of SYNGAP1 syndrome, Rett syndrome (MECP2), and an undisclosed neurodevelopmental target of shared interest. Additionally, retail pharmacy is predicted to grow at fastest CAGR during the forecast period owing to a growing accessibility to prescription drugs, facilitated by the availability of discounts provided by large retail pharmacy chains.
North America region is anticipated for the highest revenue share during the forecast period owing to the prevalence of neurodegenerative disorders and other central nervous system (CNS) diseases is on the rise, particularly in the case of Parkinson's disease. The market is characterized by the presence of numerous leading players, an increase in the development of innovative therapies, a growing awareness among the public regarding mental health, the existence of a robust pipeline of potential products, and government & non-government organizations are actively mobilizing funds to support the development and authorization of central nervous system (CNS) therapeutics. For instance, in May 2022, Minoryx has secured a funding of USD 55.4 million (EUR 51 million) to facilitate the marketing authorization applications and readiness for the launch of their therapy for X-linked Adrenoleukodystrophy (X-ALD), focusing on orphan central nervous system (CNS) disorders. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increase in government investments aimed at enhancing healthcare infrastructure. Additionally, the growing population of patients with unmet medical needs benefits from free-of-cost treatments provided by various non-profit organizations, particularly for central nervous system diseases. The government is increasingly prioritizing efforts to raise awareness about mental health and CNS therapeutics and surge in collaborations within market players. For instance, in September 2023, Sun Pharma has disclosed that one of its wholly-owned subsidiaries has engaged in a licensing agreement with US-based Pharmazz Inc. This collaboration aims to introduce the Sovateltide drug, used for the treatment of acute cerebral ischemic stroke, in the Indian market.
Segmentation: Central Nervous System Treatment Market Report 2023 - 2034
Central Nervous System Treatment Market Analysis & Forecast by Drug Class 2023 - 2034 (Revenue USD Bn)
- Decarboxylase Inhibitors
- Interferons
- Dopamine Agonists
- Antidepressants
- Immunomodulators
- Analgesics
- Others
Central Nervous System Treatment Market Analysis & Forecast by Disease 2023 - 2034 (Revenue USD Bn)
- Mental Health
- Neurovascular Diseases
- Infectious Diseases
- Neurodegenerative Diseases
- Others
Central Nervous System Treatment Market Analysis & Forecast by Drug Type 2023 - 2034 (Revenue USD Bn)
- Non-Biologics
- Biologics
Central Nervous System Treatment Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Retail Pharmacies
- Hospital Pharmacies
- Others
Central Nervous System Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Central Nervous System Treatment Market: Drug Class Estimates & Trend Analysis
8. Central Nervous System Treatment Market: Disease Estimates & Trend Analysis
9. Central Nervous System Treatment Market: Drug Class Estimates & Trend Analysis
10. Central Nervous System Treatment Market: Distribution Channel Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Central Nervous System Treatment Market
13. Europe Global Central Nervous System Treatment Market
14. Asia Pacific Global Central Nervous System Treatment Market
15. Latin America Global Central Nervous System Treatment Market
16. MEA Global Central Nervous System Treatment Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Merck & Co.
- GlaxoSmithKline PLC
- Novartis AG
- Otsuka Pharmaceutical Co. Ltd
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- AstraZeneca
- Johnson & Johnson Private Limited
- Biogen Inc.
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 136.42 Billion |
| Forecasted Market Value ( USD | $ 270.48 Billion |
| Compound Annual Growth Rate | 6.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
